Lindsay Fischer is an editor at ONN. She joined MJH life sciences in 2021 after graduating from Rutgers University with majors in both English and Spanish and a minor in creative writing. When she is not writing, or researching the latest oncology nursing news, Lindsay is an amateur backpacker and rollerblader. Email Lindsay at lfischer@mjhlifesciences.com
Abemaciclib Indication Expands to Include HR+, HER2–, Node+, High-Risk, Early Breast Cancer
March 3rd 2023Abemaciclib, in combination with endocrine therapy, had been approved as an adjuvant treatment for patients with high-risk, hormone receptor–positive, HER2-negative, node-positive, early breast cancer.
Real-World Data Confirm Ide-cel Safety and Efficacy for Patients With Multiple Myeloma
February 2nd 2023Although most patients in the real-world setting would not have met the clinical trial eligibility criteria, the efficacy and safety outcomes with idecabtagene vicleucel were similar for both sets of patients with multiple myeloma.
FDA Grants Pirtobrutinib Accelerated Approval for Relapsed/Refractory MCL
January 27th 2023Pirtobrutinib has been approved for patients with mantle cell lymphoma. The prescribing label comes with warnings for infections, hemorrhage, cytopenias, atrial fibrillation and flutter, second primary malignancies, and embryo-fetal toxicity.
Neoadjuvant Treatment Crosses Cost-Effective Threshold Vs Upfront Surgery in Pancreatic Cancer
January 27th 2023Neoadjuvant chemoradiation followed by pancreaticoduodenectomy resulted in 0.14 more quality-of-life years than upfront surgery followed by adjuvant chemotherapy in patients with resectable pancreatic cancer.